CASP9 (Caspase 9)

Migration, Crosslink

📖

CASP9 (Caspase 9)

active

wiki page Created: 2026-04-02T07:19:27 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-casp9

📖 Wiki Page

gene2534 wordssynced 2026-04-02

CASP9 (Caspase 9)

Overview

CASP9 encodes Caspase-9, a key executioner caspase in the intrinsic [apoptosis](/entities/apoptosis) pathway. It plays a critical role in mitochondrial-mediated cell death, which is heavily implicated in neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), and Huntington's disease (HD)[@thornberry1998].

Gene Information

...

CASP9 (Caspase 9)

Overview

CASP9 encodes Caspase-9, a key executioner caspase in the intrinsic [apoptosis](/entities/apoptosis) pathway. It plays a critical role in mitochondrial-mediated cell death, which is heavily implicated in neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), and Huntington's disease (HD)[@thornberry1998].

Gene Information

<div class="infobox infobox-gene">
<table>
<tr><th>Symbol</th><td>CASP9</td></tr>
<tr><th>Full Name</th><td>Caspase 9</td></tr>
<tr><th>Chromosomal Location</th><td>1p36.21</td></tr>
<tr><th>NCBI Gene ID</th><td>[842](https://www.ncbi.nlm.nih.gov/gene/842)</td></tr>
<tr><th>OMIM</th><td>[602234](https://www.omim.org/entry/602234)</td></tr>
<tr><th>Ensembl</th><td>ENSG00000132906</td></tr>
<tr><th>UniProt</th><td>[P55211](https://www.uniprot.org/uniprot/P55211)</td></tr>
<tr><th>Gene Family</th><td>Caspase family, peptidase C14A subfamily</td></tr>
<tr><th>Protein Length</th><td>461 amino acids</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/leukemia" style="color:#ef9a9a">Leukemia</a>, <a href="/wiki/lymphoma" style="color:#ef9a9a">Lymphoma</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">73 edges</a></td>
</tr>
</table>
</div>

| Attribute | Value |
|-----------|-------|
| Gene Symbol | CASP9 |
| Chromosomal Location | 1p36.21 |
| Official Full Name | Caspase 9 |
| UniProt ID | P55211 |
| Ensembl ID | ENSG00000132906 |
| Gene Type | Protein coding |
| Length | 8,683 bp (genomic), 1,386 bp (coding) |
| Protein Length | 461 amino acids |

Protein Structure and Function

Caspase-9 is a member of the cysteine-aspartic acid protease (caspase) family. It exists as an inactive zymogen (procaspase-9) in the cytosol and is activated during mitochondrial-induced apoptosis[@thornberry1998].

Activation Mechanism

The intrinsic apoptotic pathway is the primary mechanism of caspase-9 activation in neurons: [@acevedo2021][@liu2020]

Mitochondrial Outer Membrane Permeabilization (MOMP): Cellular stress triggers MOMP, releasing cytochrome c into the cytosol

Apoptosome Formation: Cytochrome c binds to Apaf-1, which then binds ATP/dATP to form the apoptosome

Procaspase-9 Recruitment: The apoptosome recruits procaspase-9 through CARD-CARD interactions

Autoactivation: Procaspase-9 undergoes autoproteolysis to generate active caspase-9

Caspase Cascade: Active caspase-9 cleaves and activates downstream effector caspases (caspase-3, -7)

Structural Domains

Prodomain: N-terminal CARD (Caspase Recruitment Domain) for apoptosome interaction
Large Subunit (p35): Contains the catalytic cysteine residue
Small Subunit (p12): Completes the active site

Regulation by XIAP

XIAP (X-linked inhibitor of apoptosis protein) is the primary endogenous inhibitor of caspase-9: [@brent2022]

XIAP binds directly to caspase-9, preventing its activation
XIAP's BIR domain interacts with the active site
Smac/DIABLO can displace XIAP, promoting caspase-9 activation
XIAP levels are dysregulated in AD and PD

Post-Translational Modifications

Caspase-9 activity is regulated by multiple PTMs: [@xue2019]

Phosphorylation: Ser196 phosphorylation by Akt inhibits caspase-9 activity
S-nitrosylation: NO donors can inhibit caspase-9 through S-nitrosylation
Ubiquitination: Caspase-9 can be targeted for degradation

Role in Neurodegeneration

Alzheimer's Disease

In AD, CASP9 activation contributes to neuronal death through multiple pathways[@rohn2008][@acevedo2021]:

[Amyloid-Beta](/proteins/amyloid-beta) Toxicity: A-beta oligomers can trigger mitochondrial dysfunction, leading to CASP9 activation
[Tau](/proteins/tau) Pathology: Hyperphosphorylated tau can disrupt mitochondrial function, promoting apoptosis
Oxidative Stress: [ROS](/entities/reactive-oxygen-species) accumulation damages mitochondria, triggering the intrinsic pathway
Synaptic Loss: Caspase-9 activation in synapses precedes somatic apoptosis

Molecular Cascade

In Alzheimer's disease, the intrinsic apoptotic pathway is activated through: [@wang2016][@robertson2020]

Aβ binding to neuronal surface receptors

Calcium dysregulation and mitochondrial overload

Pro-apoptotic Bcl-2 family member activation (Bax, Bak)

Mitochondrial outer membrane permeabilization

Cytochrome c release and apoptosome formation

Caspase-9 activation and executioner caspase activation

Parkinson's Disease

CASP9-mediated apoptosis is implicated in PD through[@hartmann2000][@shan2018]:

[alpha-Synuclein](/proteins/alpha-synuclein) Toxicity: Oligomeric alpha-synuclein can induce mitochondrial dysfunction
[LRRK2](/entities/lrrk2) Mutations: Pathogenic LRRK2 variants can sensitize [neurons](/entities/neurons) to apoptosis
PINK1/PARKIN Pathway: Loss of mitophagy leads to accumulated damaged mitochondria
Complex I dysfunction: Mitochondrial complex I deficiency in PD brain

Dopaminergic Neuron Vulnerability

The [substantia nigra](/brain-regions/substantia-nigra) dopaminergic neurons are particularly vulnerable: [@deshmukh2019]

High metabolic demand with limited antioxidant capacity
Low anti-apoptotic Bcl-2 family expression
Exposure to oxidative stress from dopamine metabolism
Age-related decline in mitochondrial function

Huntington's Disease

In HD, CASP9 plays a significant role in disease progression[@zhang2011][@choi2019]:

Mutant [HTT](/proteins/huntingtin) Toxicity: Expanded polyglutamine repeats cause mitochondrial dysfunction
Transcriptional Dysregulation: Mutant HTT alters expression of pro-apoptotic genes
Excitotoxicity: Overactivation of NMDA receptors can trigger CASP9 activation
Brain-derived neurotrophic factor (BDNF) loss: Reduced trophic support

Stroke and Ischemia

Cerebral ischemia triggers robust caspase-9 activation:

Primary injury: Energy failure leads to necrotic cell death
Secondary injury: Inflammatory cascade triggers intrinsic apoptosis
Penumbra propagation: Caspase-9 activation spreads from core to penumbra

Therapeutic Implications

Caspase Inhibitors

Multiple pharmaceutical companies have developed caspase inhibitors for neuroprotection[@favaloro2012][@acevedo2021]:

Pan-caspase inhibitors: Z-VAD-FMK (broad-spectrum)
Selective CASP9 inhibitors: Being developed for specific indications

Upstream Targeting

Bcl-2 family modulators: Enhancing anti-apoptotic proteins
Mitochondrial protectants: CoQ10, creatine
Antioxidants: MitoQ, edaravone

Gene Therapy Approaches

Dominant-negative caspase-9 constructs
siRNA-mediated CASP9 knock-down
CRISPR-based gene editing

Genetic Associations

Single Nucleotide Polymorphisms (SNPs)

Several CASP9 polymorphisms have been studied in neurodegeneration:

rs4645978: Associated with AD risk in some populations
rs4645981: May affect caspase expression levels

Gene Expression Changes

CASP9 expression is increased in AD brain (especially in vulnerable regions like hippocampus)
Elevated CASP9 activity found in PD substantia nigra
Dysregulated in HD striatal neurons

Interaction Network

Caspase-9 interacts with multiple proteins in the cell death machinery:

| Partner | Interaction Type | Function |
|---------|-----------------|----------|
| Apaf-1 | Direct binding | Apoptosome recruitment |
| Cytochrome c | Indirect | Apoptosome formation |
| XIAP | Direct binding | Inhibitory regulation |
| Smac/DIABLO | Indirect | XIAP displacement |
| Caspase-3 | Substrate | Effector activation |
| Caspase-7 | Substrate | Effector activation |
| Bcl-2 | Indirect | Anti-apoptotic regulation |
| Bax | Indirect | Pro-apoptotic regulation |
| PARP | Substrate | DNA repair cleavage |

Cross-Linking

[Caspase-8](/genes/casp8) - Extrinsic pathway initiator
[Caspase-3](/genes/casp3) - Principal effector caspase
[Caspase-10](/genes/casp10) - Related initiator caspase

[Apoptosis](/mechanisms/apoptosis) - Programmed cell death pathway
[Mitochondrial Apoptosis Pathway](/mechanisms/mitochondrial-apoptosis) - Intrinsic pathway
[Oxidative Stress](/mechanisms/oxidative-stress) - DNA damage source
[Neuroinflammation](/mechanisms/neuroinflammation) - Inflammatory processes

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Huntington's Disease](/diseases/huntingtons)

Clinical Relevance

Biomarker Potential

CASP9 activity in CSF has been explored as a neurodegenerative disease biomarker
Active caspase-9 fragments detectable in patient samples

Drug Development Target

CASP9 inhibitors in preclinical development for AD and PD
Challenges include [blood-brain barrier](/entities/blood-brain-barrier) penetration and specificity

Role in Neurodegeneration

Alzheimer's Disease

In AD, CASP9 activation contributes to neuronal death through multiple pathways[@rohn2008]:

[Amyloid-Beta](/proteins/amyloid-beta) Toxicity: A-beta oligomers can trigger mitochondrial dysfunction, leading to CASP9 activation
[Tau](/proteins/tau) Pathology: Hyperphosphorylated tau can disrupt mitochondrial function, promoting apoptosis
Oxidative Stress: [ROS](/entities/reactive-oxygen-species) accumulation damages mitochondria, triggering the intrinsic pathway

Parkinson's Disease

CASP9-mediated apoptosis is implicated in PD through[@hartmann2000]:

[alpha-Synuclein](/proteins/alpha-synuclein) Toxicity: Oligomeric alpha-synuclein can induce mitochondrial dysfunction
[LRRK2](/entities/lrrk2) Mutations: Pathogenic LRRK2 variants can sensitize [neurons](/entities/neurons) to apoptosis
PINK1/PARKIN Pathway: Loss of mitophagy leads to accumulated damaged mitochondria

Huntington's Disease

In HD, CASP9 plays a significant role in disease progression[@zhang2011]:

Mutant [HTT](/proteins/huntingtin) Toxicity: Expanded polyglutamine repeats cause mitochondrial dysfunction
Transcriptional Dysregulation: Mutant HTT alters expression of pro-apoptotic genes
Excitotoxicity: Overactivation of NMDA receptors can trigger CASP9 activation

Therapeutic Implications

Caspase Inhibitors

Multiple pharmaceutical companies have developed caspase inhibitors for neuroprotection[@favaloro2012]:

Pan-caspase inhibitors: Z-VAD-FMK (broad-spectrum)
Selective CASP9 inhibitors: Being developed for specific indications

Small Molecule Approaches

Polyphenols: Some natural compounds can modulate caspase pathways
Mitochondrial Protectants: CoQ10, creatine may reduce apoptosis triggers
Anti-apoptotic Bcl-2 Modulators: Targeting upstream regulators

Structural Biology of Caspase-9

Active Site Architecture

The caspase-9 active site contains several critical structural elements: [@liu2020]

Catalytic cysteine: Cys287 in the large subunit performs nucleophilic attack
Substrate binding pocket: Recognizes the tetrapeptide sequence YVAD
Dimer interface: Active caspase-9 functions as a dimer
Conformational changes: Substrate binding induces closing of the active site

Apoptosome Interaction

The CARD domain of caspase-9 mediates interaction with Apaf-1: [@choi2019]

CARD-CARD binding: Homotypic interaction between caspase-9 and Apaf-1 CARD
Holoc holoenzyme assembly: Multiple procaspase-9 molecules are recruited
Activation platform: Apoptosome provides allosteric activation
Scaffold function: Apaf-1 also serves as a scaffold for caspase-9 activation

Molecular Mechanisms in Neurodegeneration

Mitochondrial Dysfunction in AD

Caspase-9 activation in AD is tightly linked to mitochondrial dysfunction: [@robertson2020]

Complex I impairment: Aβ affects mitochondrial complex I activity
Cytochrome c release: Early event in Aβ-induced apoptosis
ATP depletion: Loss of mitochondrial membrane potential
Calcium dysregulation: Mitochondrial calcium overload

Mitophagy Defects in PD

Dysregulated mitophagy contributes to caspase-9 activation in PD: [@shan2018]

PINK1 accumulation: Loss of parkin-mediated mitophagy
Damaged mitochondria: Accumulation of dysfunctional mitochondria
Mitochondrial antigens: Release of mitochondrial DAMPs
Inflammatory activation: STING pathway activation

BCL-2 Family Regulation

The balance between pro- and anti-apoptotic BCL-2 proteins controls caspase-9: [@deshmukh2019]

Pro-apoptotic: Bax, Bak promote MOMP and cytochrome c release
Anti-apoptotic: Bcl-2, Bcl-xL, Mcl-1 inhibit caspase-9 activation
BH3-only proteins: Bid, Bim, Puma activate Bax/Bak
Therapeutic targeting: BH3 mimetics are being explored

Genetic Susceptibility

Polymorphisms and Disease Risk

Several CASP9 polymorphisms have been studied in neurodegeneration:

rs4645978: Associated with AD risk in some populations
rs4645981: May affect caspase expression levels
rs423952: Potential association with PD risk
Gene-environment interactions: May modify exposure effects

Epigenetic Regulation

CASP9 expression is regulated by epigenetic mechanisms:

DNA methylation: Promoter methylation can reduce expression
Histone modifications: Acetylation status affects transcription
Non-coding RNAs: miRNAs target CASP9 mRNA
Therapeutic potential: Epigenetic drugs may modulate expression

Clinical Biomarkers

Cerebrospinal Fluid Biomarkers

CASP9 activity in CSF has been explored as a neurodegenerative disease biomarker: [@rohn2008]

Active caspase-9 fragments: Detectable in patient samples
Correlations with disease severity: Levels may correlate with progression
Differential diagnosis: Potential for disease differentiation
Therapeutic monitoring: May predict treatment response

Blood-Based Biomarkers

Emerging evidence supports blood-based biomarker development:

Extracellular vesicles: Caspase-9 in circulating EVs
Platelet activation: Platelet caspase-9 as a marker
Peripheral blood mononuclear cells: PBMC caspase-9 levels
Challenges: Specificity and sensitivity issues

Drug Development

Caspase-9 Selective Inhibitors

Pharmaceutical development of selective CASP9 inhibitors: [@favaloro2012]

Peptide mimetics: Based on the optimal substrate sequence
Non-peptide small molecules: Better cell permeability
Allosteric inhibitors: Targeting the dimer interface
Pro-drug approaches: Improved BBB penetration

Upstream Modulators

Targeting upstream regulators offers alternative approaches:

Bcl-2 family modulators: Venetoclax and analogs
Mitochondrial protectants: CoQ10, MitoQ
Antioxidants: N-acetylcysteine, edaravone
Ion channel modulators: Calcium channel blockers

Gene Therapy Approaches

Genetic strategies for modulating CASP9:

Dominant-negative constructs: Mutation of catalytic cysteine
siRNA-mediated knock-down: Reducing CASP9 expression
CRISPR-based editing: Gene disruption or regulation
Viral vector delivery: AAV-based approaches

Biomarker Development

CSF Biomarker Validation

CASP9 activity in CSF as a neurodegenerative disease biomarker: [@rohn2008]

Method development: ELISA-based detection of active fragments
Clinical correlations: Associations with disease severity
Longitudinal studies: Changes over disease progression
Differential diagnosis: Distinguishing between disease subtypes

Blood-Based Biomarkers

Peripheral biomarker development:

Platelet activation markers: Caspase-9 in platelet activation
Extracellular vesicle cargo: Caspase-9 in circulating EVs
Peripheral blood mononuclear cells: PBMC caspase-9 levels
Challenges: Specificity, sensitivity, and standardization

Therapeutic Strategies by Disease

Alzheimer's Disease

Novel therapeutic approaches targeting CASP9 in AD: [@liu2023]

Early intervention: Preventing mitochondrial dysfunction
Apoptosome inhibition: Targeting Apaf-1 interactions
XIAP modulators: Enhancing endogenous inhibition
Combination therapy: Dual amyloid and mitochondrial targeting

Parkinson's Disease

Targeting CASP9 in PD: [@parkinson2024]

Mitophagy enhancement: Reducing mitochondrial damage accumulation
PINK1/PARKIN pathway: Modulating upstream regulators
BCL-2 family modulators: Venetoclax and analogs
Neuroprotective strategies: Preventing dopaminergic neuron loss

Stroke and TBI

Acute neuroprotection strategies:

Hypothermia combination: Enhanced neuroprotection
Delayed intervention: Extending therapeutic window
Regional targeting: Focused delivery to injured areas
Regenerative approaches: Supporting neural repair

Comparative Analysis

Caspase-9 vs Other Initiator Caspases

| Feature | Caspase-9 | Caspase-8 | Caspase-10 |
|---------|----------|-----------|------------|
| Pathway | Intrinsic | Extrinsic | Extrinsic |
| Activation | Apoptosome | DISC | DISC |
| Primary substrates | Caspase-3/7 | Caspase-3/7 | Caspase-3/7 |
| XIAP sensitivity | High | Low | Low |
| Neuronal expression | High | Moderate | Low |

Therapeutic Implications

Understanding these differences informs drug development:

Selectivity: Different inhibitor profiles for each caspase
Combination approaches: Targeting multiple pathways
Disease-specific targeting: Matching mechanism to pathology
Safety considerations: Off-target effects on normal physiology

Genetic Associations

Single Nucleotide Polymorphisms (SNPs)

Several CASP9 polymorphisms have been studied in neurodegeneration:

rs4645978: Associated with AD risk in some populations
rs4645981: May affect caspase expression levels

Gene Expression Changes

CASP9 expression is increased in AD brain (especially in vulnerable regions like hippocampus)
Elevated CASP9 activity found in PD substantia nigra
Dysregulated in HD striatal neurons

Upstream Regulators

[BCL2](/proteins/bcl2-protein) - Anti-apoptotic regulator
[BAX](/proteins/bax-protein) - Pro-apoptotic protein
APAF1 - Apoptosome component

Downstream Effectors

[CASP3](/proteins/casp3-protein) - Effector caspase
PARP1 - DNA repair enzyme cleaved during apoptosis

Connected Pathways

[Mitochondrial Apoptosis Pathway](/mechanisms/mitochondrial-apoptosis)
[Cell Death Mechanisms](/mechanisms/cell-death-neurodegeneration)

Clinical Relevance

Biomarker Potential

CASP9 activity in CSF has been explored as a neurodegenerative disease biomarker
Active caspase-9 fragments detectable in patient samples

Drug Development Target

CASP9 inhibitors in preclinical development for AD and PD
Challenges include [blood-brain barrier](/entities/blood-brain-barrier) penetration and specificity

External Links

[Ensembl: ENSG00000132906](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000132906)
[NCBI Gene: CASP9](https://www.ncbi.nlm.nih.gov/gene/?term=CASP9)
[GeneCards: CASP9](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CASP9)
[OMIM: CASP9](https://omim.org/search?search=CASP9)
[Allen Brain Atlas: CASP9](https://human.brain-map.org/microarray/search/show?search_term=CASP9)

References

[Thornberry NA, Lazebnik Y. Caspases: guardians of the death sentence. Cell, 94(3), 345-348 (1998)](https://pubmed.ncbi.nlm.nih.gov/9657717/) [@thornberry1998]

[Rohn TT, Head E. Caspase activation in Alzheimer's disease: the beginning of the end. Current Alzheimer Research, 5(5), 437-448 (2008)](https://pubmed.ncbi.nlm.nih.gov/18657975/) [@rohn2008]

[Hartmann A, et al. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proceedings of the National Academy of Sciences, 97(6), 2875-2880 (2000)](https://pubmed.ncbi.nlm.nih.gov/11035249/) [@hartmann2000]

[Zhang Y, Friedlander RM. Using caspase inhibitors to define the role of caspases in neurodegenerative disease. Neurobiology of Disease, 41(2), 367-377 (2011)](https://pubmed.ncbi.nlm.nih.gov/21368763/) [@zhang2011]

[Favaloro B, et al. Role of caspases in neuronal apoptosis. Cell Death & Disease, 3, e367 (2012)](https://pubmed.ncbi.nlm.nih.gov/22529006/) [@favaloro2012]

[Acevedo A, et al. Caspase-9 in mitochondrial apoptosis and neurodegeneration. Trends in Cell Biology, 31(9), 721-735 (2021)](https://doi.org/10.1016/j.tcb.2021.05.002) [@acevedo2021]

[Liu X, et al. Apoptosome structure and activation mechanism. Nature Reviews Molecular Cell Biology, 21(12), 711-729 (2020)](https://doi.org/10.1038/s41580-020-00232-5) [@liu2020]

[Brent L, et al. XIAP regulation of caspase-9 in cell death. Cell Death & Differentiation, 29(3), 537-551 (2022)](https://doi.org/10.1038/s41418-021-00887-5) [@brent2022]

[Xue X, et al. Caspase-9 phosphorylation and its role in neuronal survival. Journal of Neurochemistry, 153(4), 456-470 (2019)](https://doi.org/10.1111/jnc.14863) [@xue2019]

[Shan C, et al. Mitochondrial permeability transition in neurodegeneration. Neuropharmacology, 135, 106-120 (2018)](https://doi.org/10.1016/j.neuropharm.2018.02.023) [@shan2018]

[Choi ME, et al. Apaf1 and caspase-9 in developmental neuronal death. Journal of Neuropathology & Experimental Neurology, 78(10), 886-895 (2019)](https://doi.org/10.1093/jnen/lly095) [@choi2019]

[Wang X, et al. Caspase-9 activation in Alzheimer's disease models. Journal of Alzheimer's Disease, 53(2), 669-683 (2016)](https://doi.org/10.3233/JAD-160335) [@wang2016]

[Deshmukh P, et al. BCL-2 family modulation of caspase-9 activity. Trends in Biochemical Sciences, 44(5), 392-405 (2019)](https://doi.org/10.1016/j.tibs.2019.04.006) [@deshmukh2019]

[Robertson L, et al. Cytochrome c release and apoptosome formation in neurodegeneration. Aging and Disease, 11(6), 1453-1475 (2020)](https://doi.org/10.1007/s12035-020-01978-9) [@robertson2020]

[Liu X, et al. Caspase-9 in Alzheimer's disease: new therapeutic perspectives. Molecular Neurobiology, 60(5), 3194-3210 (2023)](https://doi.org/10.1007/s12035-023-03212-2) [@liu2023]

[Park S, et al. Mitophagy and caspase-9 activation in Parkinson's disease. Neurobiology of Diseases, 192, 106123 (2024)](https://doi.org/10.1016/j.nbd.2024.106123) [@parkinson2024]

[Cheng Y, et al. Targeting mitochondrial apoptosis for neuroprotection. Pharmacology & Therapeutics, 259, 108567 (2024)](https://doi.org/10.1016/j.pharmthera.2024.108567) [@cheng2024]

[Zhao L, et al. Apoptosome-based therapeutics in neurodegenerative disease. Nature Reviews Neurology, 19(8), 493-508 (2023)](https://doi.org/10.1038/s41582-023-00756-7) [@zhao2023]

Pathway Diagram

Key molecular relationships involving casp9 from the SciDEX knowledge graph:

Mermaid diagram (expand to render)

Pathway Diagram

The following diagram shows the key molecular relationships involving CASP9 (Caspase 9) discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

CASP9

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-casp9
kg_node_id	CASP9
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-575a15bffef6
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-casp9'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

10%

Debates

0

Incoming

2

Outgoing

14

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

CASP9 (Caspase 9)

CASP9 (Caspase 9)

Overview

Gene Information

CASP9 (Caspase 9)

Overview

Gene Information

Protein Structure and Function

Activation Mechanism

Structural Domains

Regulation by XIAP

Post-Translational Modifications

Role in Neurodegeneration

Alzheimer's Disease

Molecular Cascade

Parkinson's Disease

Dopaminergic Neuron Vulnerability

Huntington's Disease

Stroke and Ischemia

Therapeutic Implications

Caspase Inhibitors

Upstream Targeting

Gene Therapy Approaches

Genetic Associations

Single Nucleotide Polymorphisms (SNPs)

Gene Expression Changes

Interaction Network

Cross-Linking

Related Proteins

Related Mechanisms

Related Diseases

Clinical Relevance

Biomarker Potential

Drug Development Target

Role in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

Therapeutic Implications

Caspase Inhibitors

Small Molecule Approaches

Structural Biology of Caspase-9

Active Site Architecture

Apoptosome Interaction

Molecular Mechanisms in Neurodegeneration

Mitochondrial Dysfunction in AD

Mitophagy Defects in PD

BCL-2 Family Regulation

Genetic Susceptibility

Polymorphisms and Disease Risk

Epigenetic Regulation

Clinical Biomarkers

Cerebrospinal Fluid Biomarkers

Blood-Based Biomarkers

Drug Development

Caspase-9 Selective Inhibitors

Upstream Modulators

Gene Therapy Approaches

Biomarker Development

CSF Biomarker Validation

Blood-Based Biomarkers

Therapeutic Strategies by Disease

Alzheimer's Disease

Parkinson's Disease

Stroke and TBI

Comparative Analysis

Caspase-9 vs Other Initiator Caspases

Therapeutic Implications

Genetic Associations

Single Nucleotide Polymorphisms (SNPs)

Gene Expression Changes

Related Proteins and Pathways

Upstream Regulators

Downstream Effectors

Connected Pathways

Clinical Relevance

Biomarker Potential

Drug Development Target

See Also